Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.

[1]  J. Carles,et al.  Patient-reported outcomes (PROs) among men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase 3 study (TALAPRO-2). , 2023, Journal of Clinical Oncology.

[2]  A. Kishan,et al.  Meta-Analysis of Candidate Surrogate End Points in Advanced Prostate Cancer. , 2023, NEJM evidence.

[3]  A. Armstrong,et al.  Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2022, NEJM evidence.

[4]  A. Armstrong,et al.  Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial. , 2022, Journal of Clinical Oncology.

[5]  F. Saad,et al.  Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer , 2021, Cancers.

[6]  R. Ionescu-Ittu,et al.  Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors , 2021, Advances in Therapy.

[7]  F. Saad,et al.  Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.

[8]  C. Parker,et al.  Prostate Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  F. Saad,et al.  Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. , 2020, European urology.

[10]  F. Saad,et al.  Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.

[11]  F. Lordick,et al.  Association of Disease Progression With Health-Related Quality of Life Among Adults With Breast, Lung, Pancreatic, and Colorectal Cancer , 2020, JAMA network open.

[12]  P. Kantoff,et al.  Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry , 2019, Prostate Cancer and Prostatic Diseases.

[13]  C. Bokemeyer,et al.  Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines† , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  F. Saad,et al.  Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. , 2018, The Lancet. Oncology.

[15]  M. Morris,et al.  Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial , 2018, JAMA oncology.

[16]  L. Eliasson,et al.  Patients' Preferences for the Treatment of Metastatic Castrate-resistant Prostate Cancer: A Discrete Choice Experiment. , 2017, Clinical therapeutics.

[17]  Oliver Sartor,et al.  Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  F. Saad,et al.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. , 2015, The Lancet. Oncology.

[19]  R. Eeles,et al.  Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease , 2014, British Journal of Cancer.

[20]  H. Hieronymus,et al.  Androgen receptor signaling regulates DNA repair in prostate cancers. , 2013, Cancer discovery.

[21]  F. Feng,et al.  A hormone-DNA repair circuit governs the response to genotoxic insult. , 2013, Cancer discovery.

[22]  R. Eeles,et al.  Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  P. Scardino,et al.  Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer , 2010, Clinical Cancer Research.

[24]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Bono,et al.  Commentary on: Abiraterone in Metastatic Prostate Cancer Without Previous Chemotherapy , 2013 .